semaglutide bpc-157 + (Peptide Therapy) at Total Body Wellness semaglutide bpc-157 semaglutide and bpc

Biochemical Pharmacology 42 , 17171720, doi:10.1016/0006-2952(91)90507-2 (1991)

HbA1c reductions up to 1.6 percentage points Weight trajectory: Weight loss had not plateaued by 52 weeks, indicating potential for further reduction with continued treatment Cardiometabolic: Improvements in waist circumference, blood pressure, hs-CRP, and lipid parameters Evidence level: Moderate -- well-designed phase 2 with NEJM publication, but single trial, no head-to-head comparisons

Metabolism of dietary and microbial vitamin B family in the regulation of host immunity

Comparing initial CMR imaging to 24 months demonstrated improvement in LVEF and RVEF from 40% to 66% and 41% to 64%, respectively, with normalized ventricular volumes and mass